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Objective: Analyse the evolution of biological tumour necrosis factor alpha (TNFalpha) 
inhibitors utilisation in the treatment of rheumatoid arthritis (RA) and identify the reasons for 
the observed variation. 
Methods: Two western European countries were selected for this analysis, Portugal and the 
Netherlands. Country characteristics, treatment guidelines and RA prevalence were obtained 
from the literature. Patient characteristics were obtained from the literature and from the data 
made available by the University Medical Center Utrecht, for Portugal and the Netherlands, 
respectively. Annual utilisation rates of TNFalpha inhibitors between 2008 and 2013 were 
expressed as defined daily doses (DDDs)/1000 inhabitants/day.  
Results: TNFalpha inhibitors utilisation varied from 0.18, in 2008, to 0.46 DDDs/1000 
inhabitants/day, in 2013, in Portugal and from 0.98, in 2008, to 1.64 DDDs/1000 
inhabitants/day, in 2013, in the Netherlands. Clinical guidelines, variations in GDP per capita, 
total health expenditure, medical goods expenditure and drug distribution channel, appear to 
have had limited impact on TNFalpha inhibitors utilisation. On average, Dutch RA patients 
under therapy with TNFalpha inhibitors appear to younger than their Portuguese counterparts.  
Conclusions: TNFalpha inhibitors utilisation continues to be increasing, despite the negative 
influences caused by the economic recession and posterior austerity measures. This increase 
in TNFalpha inhibitors utilisation was not equal in Portugal and in the Netherlands, which lead 
to a bigger difference in utilisation between both countries. The high percentage of 
undiagnosed Portuguese rheumatic patients might be one of the leading reasons for the 
anaemic utilization of TNFalpha inhibitors. The number of rheumatologists per 100,000 
inhabitants, improved clinical efficiency and a reduction in drug pricing all seem to have 














Objetivo: Analisar a utilização dos biológicos inibidores do fator de necrose tumoral alfa (TNF-
alfa) no tratamento de artrite reumatoide (AR) e identificar as razões para a variação de 
utilização observada. 
Metodologia: Dois países europeus ocidentais foram selecionados para esta analise, 
Portugal e a Holanda. As características dos países, guidelines de tratamento e a prevalência 
foram obtidos da literatura. As características dos doentes com AR foram obtidas da literatura 
e a partir dos dados disponibilizados pelo University Medical Center Utrecht, para Portugal e 
Holanda, respetivamente. Ratios de utilização anuais dos inibidores do TNF-alfa entre 2008 e 
2013 foram demonstrados como Dose Definida Diária (DDD)/1000 habitantes/dia. 
Resultados: A utilização dos inibidores do TNF-alfa variaram de 0.18, em 2008, para 0.46 
DDD/habitantes/dia, em 2013, em Portugal e de 0.98, em 2008, para 1.64 DDD/habitantes/dia, 
em 2013, na Holanda. Guidelines clinicas, variações no GDP per capita, despesa total em 
saúde, despesa com produtos de saúde e canal de distribuição dos medicamentos, parecem 
ter tido um impacto limitado na utilização dos inibidores do TNF-alfa. Doentes holandeses com 
artrite reumatóide sob terapia dos inibidores do TNF-alfa são, em média, mais novos que os 
seus contrapartes portugueses. 
Conclusão: A utilização de inibidores do TNF-alfa continua a aumentar, mesmo com os 
efeitos negativos causados pela recessão económica e das medidas de austeridade 
implementas posteriormente. O aumento de utilização de inibidores do TNF-alfa não foi igual 
em Portugal e na Holanda, levando assim a um aumento na diferença de utilização destes 
medicamentos entre os dois países. A elevada percentagem de doentes portugueses não-
diagnosticados pode ser uma das principais razões por detrás da utilização anémica de 
inibidores do TNF-alfa. O número de reumatologistas por 100.000 habitantes, aumento da 
eficiência clinica e reduções no preço dos fármacos parecem todos ser fatores que 
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The Universal Declaration of Human Rights states that “Everyone has the right to a standard 
of living adequate for the health and well-being of himself and of his family, including food, 
clothing, housing and medical care and necessary social services, and the right to security in 
the event of unemployment, sickness, disability, widowhood, old age or other lack of livelihood 
in circumstances beyond his control”(1). This is a common commitment of all western 
European democracies, however, making this dream a reality seems as difficult as it was in 
1948. It is undeniable that there have been many improvements over since the last century, 
human life expectancy, for example, has improved at a rate of more than 3 years per decade 
since 1950, with the only exception being the 90’s decade(2). But as people age, more 
comorbidities start to develop, driving the need for more and better medical care. The result of 
this ever-increasing need for healthcare is clear, according to Eurostat, the average healthcare 
expenditure relative to Gross Domestic Product (GDP) in the European Union (EU) in 2013 
was around 9.4% and the fact that new and more effective medication is becoming available 
seems to question the ideal of equal drug accessibility for all citizens. Biologics such as Tumour 
Necrosis Factor alpha (TNFalpha) inhibitors are now part of the therapeutical arsenal against 
Rheumatoid Arthritis (RA), but the costs associated with these drugs force many policymakers 
to impose certain limitations on their clinical application, effectively limiting their widespread 
use. This type of decisions is certainly not new and don’t apply only to these specific drugs, in 
fact, they have become an unwanted but required widespread phenomenon.  
Drug utilization inequality between countries, a direct consequence of these restrictions, has 
been widely studied, particularly in the case of TNFalpha inhibitors and it seems to be 
somewhat correlated to a number of factors such as GDP, expenditure on health, access and 
availability of care, global drug prices and clinical guidelines(3–7). Portugal and the 
Netherlands are two European countries with significant differences in these factors, which 
might explain the different utilisation of TNFalpha inhibitors, in defined daily dose (DDD)/1000 
inhabitants/day, noted in past studies(5). But this paradigm might have slightly shifted since 
2008, when both countries, while under an economic recession, were required to reduce their 
healthcare expenditure, while still maintaining adequate access to new and expensive drugs. 
One of the solutions for the increasing prices of innovative drugs has been to centralise the 
distribution pathway in the hospital sector, effectively increasing their bargaining power in 
hopes of driving down prices and increasing sustainability. This system, when compared to the 
retail distribution channel, has the disadvantage of being a more controlled process due to the 
hospital’s budgetary constraints and the long and complicated procedures required to take to 
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authorise certain medical prescriptions. Despite these limitations, it has become the model of 
many European countries, including the Netherlands that since 2012 transferred many drugs, 
including TNFalpha inhibitors, from the retail to the hospital distribution channel. Portugal 
which has functioned with this model before the financial crisis has also enacted some policy 
measures to limit hospital expenditure, as for example the 2010 dispatch which forced 
hospitals in the following years to only acquired medication with a price 7,5% inferior to that 
practised in 2010(8). It isn’t clear how these policies have affected drug utilization, but they 
serve as a reminder of the precarious situations that policymakers, health professionals and 
patients are in during this decade. It is easy to argue that RA patients all over Western Europe 
have now an average quality of life superior to their last century counterparts, but it is still 
unclear if we be able to adapt to the current challenges and maintain the premises envisioned 
by the United Nations in 1948. This thesis aims to explore the variation of TNFalpha inhibitors 
utilization in the treatment of RA as a measure of access to treatment thru a cross-national 
comparison of Portugal and the Netherlands. 
1.1. Rheumatoid Arthritis  
1.1.1. Definition and classification criteria for RA 
RA is a systemic, autoimmune disease of unknown aetiology that results in chronic 
inflammation that causes the synovium to thicken, resulting in swelling and pain in and around 
the joints. If left unchecked, it can lead to cartilage and bone destruction resulting in a joint 
deformity that cannot be reversed, and thus a large effort has been put into place to guaranty 
an early diagnosis and aggressive treatment to control RA(9–11). RA is classified as an auto-
immune disease, due to the presence of autoantibodies, such as rheumatoid factor (RF) and 
anti-citrullinated protein antibody (ACPA), which may precede the clinical manifestation of RA 
by many years(12,13). This emphasis on early diagnosis has led to a joint effort of the 
American College of Rheumatology (ACR) and the European League Against Rheumatism 
(EULAR) to review the 1987 RA classification criteria, and thus create the 2010 Rheumatoid 
Arthritis Classification Criteria which focuses on the detection of the earlier stages of disease 
that are associated with persistent and/or erosive disease, such as RF and ACPA, rather than 




Figure 1 - The 2010 American College of Rheumatology/European League Against Rheumatism classification 
criteria for RA. A score of ≥6/10 is needed for classification of a patient as having definite RA. (15)  
1.1.2. Prevalence and incidence  
It is estimated that the prevalence of RA is approximately 0.5% to 1% of the adult 
population(16), varying according to the country and region under analyses(16). For example, 
Southern European countries are estimated to have a lower prevalence than for Northern 
Europe, while highest rates are found in North America(17,18). Portugal’s and The 
Netherlands RA prevalence was estimated by Kobelt et al as 0.47% and 0.46%(19), 
respectively, for patients older than 19.   
An epidemiological study was recently conducted in Portugal by EpiReumaPt, to produce more 
data regarding rheumatic and musculoskeletal diseases (RMDs) prevalence. This was an 
observational and cross-sectional population-based study, with a selected sample of 10.661 
individuals, that estimated an RA prevalence of approximately 0.7%(20), a prevalence slightly 
higher, around 0,2%, than in Kobelt et al(19). This difference in prevalence might be due to a 
variety of factors, such as a difference in RA diagnostic tolls, changes in demographics and 
the degree of uncertainty inherently generated by the estimation that Kobelt et al(19) made for 
many countries, including Portugal.  
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Despite all of this, Kobelt et al(19) is the only report currently available that allows for a direct 
comparison of RA prevalence between European countries.    
Country 
Prevalence > 19 
(%) 
Denmark 0.58 
United Kingdom 0.57 
Ireland 0.49 
Greece  0.48 
France  0.48 
Austria 0.47 
Portugal 0.47 
Netherlands  0.46 
Table 1 - Prevalence rates and the estimated number of patients (>19) per Country (adapted). (19) 
Women have, in most studies, a higher incidence of RA of around 2:1 to 3:1, when compared 
to male individuals, suggesting that reproductive and hormonal factors might be influential. 
There also seems to be a peak in disease onset during the fifth decade of life, as we can 
observe in annex 1. Smoking habits, infectious agents, ethnicity, genetic, socioeconomic, 
hormonal and dietary factors, all seem to be related to an increased incidence of RA, but there 
is still a debate regarding the strength of their influence.(16,21–24)     
1.1.3. Mortality and morbidity 
Mortality has been positively associated with RA, several studies show an increased mortality 
in patients with RA when compared with expected rates in the general population(25–27). The 
standardised mortality for patients with RA ratios varies from 1.28 to 2.9 and there is evidence 
that these patients have not experienced the same improvement in survival as the general 
population, resulting in a widening of the mortality gap(27-28). The possible causes of this 
higher mortality include increased risk from cardiovascular, respiratory, hematologic, 
gastrointestinal and infectious diseases(27). New treatment options such as methotrexate 
(MTX) and TNFalpha inhibitors appear to improve patient survival, due to their ability to 
dramatically reduce disease activity and the development of comorbidities(29,30).  
In Europe, there are more than 120 million people affected by RMDs which are considered the 
number one cause of disability in Europe. These are one of the main causes of absenteeism, 
work loss and early retirement. In addition, RMDs have a yearly economic burden of more than 
€ 240 billion on public budgets in Europe(31). 
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Disability-Adjusted Life Years (DALY’s), measured according to the gap between current 
health status and the ideal health situation where the entire population lives, is divided into two 
inputs, mortality (years of life lost) and disability (years of disability). In RA the greatest share 
of the disease burden is caused by disability, significantly different from other diseases with a 
predominant component in mortality, such as cancer and cardiovascular disease, as observed 
in annex 2(19). Mean utility in RA is low, approximately 0.5, and is showed to rapidly decreases 
utility from the onset of the disease(19). When patients with RA are compared to the general 
population, in an age-matched sample, the loss of quality of life varies from 20 to 30%.(19,32) 
1.2. Treatment of rheumatoid arthritis 
The management of RA rests on several principles. Drug treatment, which comprises disease-
modifying antirheumatic drugs (DMARDs), nonsteroidal anti-inflammatory drugs and 
glucocorticoids (GCs), and non-pharmacological measures, such as physical, occupational 
and psychological therapeutic approaches(33). The agreed standard of care relies mainly on 
the use DMARDs as the principal option of treatment, since these drugs can reduce or reverse 
the main signs and symptoms of this disease and thus improve the overall quality of life. 
DMARDs are divided into two major classes: synthetic and biological, denominated as 
sDMARDs and bDMARDs, respectively. A new nomenclature proposed in 2013 proposed a 
new terminology, enabling a greater differentiation between the drugs belonging to each 
class(34). The conventional sDMARDs (csDMARDs) includes chemical agents such as MTX, 
sulfasalazine and leflunomide, whereas the subclass targeted sDMARDs (tsDMARDs) 
includes drugs such as tofacitinib. The bDMARD class is divided two subclasses, the biological 
originator boDMARDs and the biosimilar DMARD (bsDMARDs)(34). 
1.2.1. Biological DMARDs  
The need for new and innovative treatment options for diseases led many pharmaceutical 
companies to engage in the development of biologic drugs, which now account for 
approximately 27% of the pharmaceutical sales in Europe and have grown at a rate of 5.5% in 
value sales between 2012 and 2013(35).  
For RA this evolution has been evident and is a major consequence of a deeper understanding 
of the pathophysiological and immunological mechanisms that trigger this disease. bDMARDs 
have proven to be an effective therapeutically option, either in monotherapy or in combination 
with a sDMARDs, such as MTX(36). Clear differences in effectiveness between bDMARDs 
have still not been detected, although there is some evidence of the superiority of tocilizumab 
8 mg/kg monotherapy versus adalimumab 40 mg subcutaneous monotherapy group(37). 
To date, nine boDMARDs have been approved for the treatment of RA:  
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• TNFalpha inhibitors - infliximab, etanercept, adalimumab, golimumab and certolizumab 
pegol; 
• Interleukin (IL)-1 blocker – anakinra; 
• IL-6 blocker - tocilizumab; 
• B-cell depleting agent – rituximab; 
• T-cell co-stimulation inhibitor – abatacept. 
 
1.2.2. TNFalpha inhibitors 
TNFalpha is a cytokine that plays an important role in joint inflammation. TNFalpha inhibitors 
target this cytokine, despite their small differences in molecular structure, pharmacodynamics 
and pharmacokinetics. Presently there are five TNFalpha inhibitors approved in the EU for the 
treatment of RA, differing from each other due to their molecular structure, approved dosage 
and administration route, as can be seen in figure 2.  
 
Figure 2 - TNFalpha inhibitors approved for the treatment of RA. (15) 
The main deterrent for the widespread use of TNFalpha inhibitors is their price and 
consequently their cost-effectiveness. In the United States, the average daily cost of a biologic 
is $45 compared with only $2 of csDMARDs (38). In 2015, Remicade® the reference infliximab 
product had a list price in The Netherlands of €602.43 per vial of 100mg(39). 
The debate about the cost-effectiveness of TNFalpha inhibitors is a recurrent theme, mainly 
because most economic evaluation only show cost-effectiveness when the willingness to pay 
(WTP) is of 50,000–100,000 €/Quality-adjusted life years (QALYS) among patients with 
insufficient treatment response to cDMARD but not in cDMARD naïve patients. Among patients 
with an inadequate response to cDMARDs, biologics were associated with an incremental 
cost-effectiveness ratio (ICERs) ranging from 12,000 to 708,000 €/QALY, with no clear 




1.2.3. Biosimilar DMARDs  
A biosimilar medicine is a biological medicine that is developed to be “similar” to an existing 
biological medicine, they are not generic drugs, which have simpler chemical structures and 
are identical to their reference medicines. The active substance of a biosimilar and its reference 
medicine are essentially the same biological substance, but with some minor structural 
differences, that result from their complex nature and production methods. These biosimilar 
drugs must be approved by the European Medicines Agency (EMA) and will follow the same 
rigorous regulatory assessments as all other biopharmaceuticals. If the reference drug has 
been authorised in the EU for several years, and its clinical benefit is well established, some 
studies carried out with the reference medicine may not need to be reproduced for the 
biosimilar(41). Once, and if, a market authorization is granted through this centralised 
procedure the biosimilar drug will be valid in all EU member states(42).  
Until 2016, four bsDMARDs have been approved for the treatment of RA, as displayed in 
Table 2. 
Medicine Name Active Substance Authorization Date 
Benepali® Etanercept 14/01/2016 
Flixabi® Infliximab 26/05/2016 
Inflectra® Infliximab 10/09/2013 
Remsima® Infliximab 10/09/2013 
Table 2 - BsDMARDs approved for the treatment of RA. 
Source: EMA 
 
Since the quality, safety and effectiveness of this drugs are “similar” to the reference drug the 
question about switching, interchangeability and substitution arises and is subject to debate 
across Western European countries. 
In the case of infliximab biosimilar, there is a clear divide in standing, with some countries with 
a more “pro-switching” approach like Norway, Denmark, Netherlands and Germany, and the 
more “resistant” markets such as France, Italy, and Portugal, as noted in figure 3. The main 
reason for this disparity is not necessarily the “discount rate”, which is the percentage of the 
biosimilar price reduction when compared to the initial originator price, since although some 
countries present approximately the same “discount rate” there are still significant differences 
in the level of biosimilar uptake (e.g. Spain and The Netherlands)(43). The main reason 
appears to be the lack of data and experience with biosimilar infliximab and the ethical 




Figure 3- Likelihood of Infliximab Biosimilar prescribing, answers presented on 1-5 rating (Green-5/Red- 1). (43) 
There is no uniform “discount rate” for biosimilars in European countries since it varies greatly 
according to each country’s biosimilar policy that defines the maximum price for the first 
generic drug that will enter the market, as we as we can observe in annex 3. Portugal defines 
drug pricing according to rules and criteria set for non-generics (international reference 
pricing), based on the average ex-factory price observed in the 3 reference countries and sets 
as a maximum value 80% of the ex-factory price set for the biological medicine of 
reference(44). The Netherlands reference price for a biosimilar is set in the same way as for 
all other medicines, using external price referencing of four reference countries(45). Discounts 
rates for biosimilars are on average 25%, but it can reach up to 70%(43,46).  
Another important factor that must be taken into consideration is the delay that exists between 
the patent expiration date and the first sale of the biosimilar drug. It is always advisable to have 
the biosimilar enter the market as soon as possible since it allows health professionals time to 
adapt to the new product and to change clinical guidelines.  
Portugal was quick to implement biosimilars of infliximab as a therapeutical option for 
rheumatic patients, with their first recorded sale in 2013, while the Netherlands first sale was 
only in 2015(47). It is very difficult to determine exactly how much money biosimilars save in 
the treatment of RA patients, but according to a study published by Jha. Et al(39), the estimated 
drug expenditure savings generated in the first year after the introduction in the Netherlands 
of the biosimilar Remsima® with a “discount rate” of 30%, an uptake of 25% in patients that 
perform switching from Remicade® and a 50% utilisation in the naïve patients, would be 
approximately 0.722 million euros. When taking into account that the “discount rate” for 
biosimilars of infliximab is currently approximately 37% and 50%(43,46), in Portugal and in the 
Netherlands, respectively, we start to understand how in the future biosimilars will improve our 




1.2.4. Treatment strategies for RA 
There is a great variety of data regarding clinical and observational trials on drugs and 
strategies for RA, but all this information also results in some inconsistencies that confuse 
patients and rheumatologists, resulting in poor decision making when selecting therapeutic 
strategies for this disease. This has led the EULAR to develop management guidelines for RA, 
the first in 2010 and later on its update in 2013 (32,36). The Netherlands and Portugal have 
their own guidelines for the treatment of RA, dating back to 2009 and 2011, respectively, and 
both derive in from the EULAR guidelines previously mentioned (48,49).  
1.2.5. EULAR guidelines for the therapeutical management of RA 
The 2013 recommendations reflect the balance of efficacy and safety of DMARDs, with little 
emphasis on the toxicity of these drugs, as it can be seen in annex 4. As included in the 
previous guideline of 2010, treatment should start with DMARDs, MTX if possible, as soon as 
the diagnosis of RA is confirmed and in patients with insufficient response to MTX and/or other 
sDMARDs with or without GCs, bDMARDs, particularly TNFalpha inhibitor, should be 
added(33,37). Several studies have demonstrated the efficacy and safety of biologic drugs in 
RA patients particularly in combination with MTX, although it should be noted that monotherapy 
is not advisable as a first treatment option(36). 
The 2013 guideline also includes the possibility of biosimilar use, although it doesn’t explicitly 
instruct readers on which option, reference product vs biosimilar, to use. The definition of 
remission has also been altered and is now by the ACR/EULAR published criteria(50), instead 
of the Disease Activity Score based on 28 joint counts (DAS28), used in previous guidelines.  
1.2.6. Portuguese guidelines for the use of biological agents for RA 
The Portuguese Society of Rheumatology (SPR) presented a guideline with the purpose of 
establishing criteria for the introduction and maintenance of biological agents, as well as the 
contraindications and procedures in the case of non-responders. Some of the criteria used 
have close similarities to the EULAR 2010 guidelines as it was published one year after said 
document. The criteria proposed were(49): 
1) “Patients who fail or have an inadequate response to cDMARDs are eligible for treatment 
with biological therapies. To determine the response as inadequate, a patient must present 
one of the following situations:  
a) DAS ≥ 3.2 or 
b) 2.6 ≤ DAS < 3.2 and worsening of health assessment questionnaire (HAQ)≥0.22 (6/6M) 
or worsening x-ray scores: Larsen ≥6/SvdH ≥5 (12/12M)  
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2) Patients with an inadequate response to MTX used in a stable dose of at least 20 mg/week, 
orally or parenterally, for at least 3 months, may proceed with biological therapy, 
particularly in patients with severe prognostic markers, or may consider further treatment 
with another cDMARD or association of cDMARDs during at least 3 months before starting 
a biological agent, preferably in patients without a severe prognosis. 
3) In the case of intolerance, toxicity or refusal to take MTX, the patient may be considered 
eligible for treatment with a biological agent if there is an inadequate response after a 
period of at least 3 months of treatment with another cDMARD or an association of 
cDMARDs”.  
1.2.7. Netherlands guidelines for the use of biological agents for RA 
The treatment of RA in the Netherlands is described in the Kwaliteitsinstituut voor de 
Gezondheidszorg CBO (CBO)/Nederlandse Vereniging voor Reumatologie (NVR) guideline 
published in 2009, the international EULAR guideline of 2013(37) and the 2014 directive of the 
Dutch Society for Rheumatology. And thus, it retains the basic principles of initial therapy of 
RA with csDMARDs and glucocorticoids. If this therapeutical approach doesn’t reach intended 
therapeutically target, DAS28> 3.2, in patients treated for a sufficient time period bDMARDs 
may be considered(48).  
1.3. Dutch healthcare system: 
The healthcare system in The Netherlands is operated by private health insurances companies 
that comply with certain public social conditions expensed under the “Health Insurance Act” of 
2006. It is mandatory for all residents to enrol on a basic health insurance which consists of a 
standard package of insured services. Insured patients have the right to reimbursement for 
medicinal products included in the positive list of the Drugs Remuneration System (DRS). The 
“preference policy” states that health insurers are obliged to appoint at least one medicinal 
product of all the medicinal products with the same active substance available within the 
positive list DRS. In the inpatient setting, where biologic drugs such as TNFalpha inhibitors are 
dispensed since 2012, the availability of medicinal products used in a given hospital is decided 
by each hospital’s administration board and has their expenses covered by the health 
insurances according to each diagnosis treatment combination (DTCs)(51). 
The Dutch healthcare system has been under a hot debate during the last decades, mainly 
due to the high public expenditure required to keep the system running. Despite this, there 
seems to be a consensus regarding the high quality of service and good health outcomes that 
patients can expect. A poll conducted in 2013, showed that 91% of the population evaluate the 
quality of the healthcare system in the Netherlands as good, with 43% still saying that there 
was still a need to implement further reforms(52).  
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1.3.1. Pharmaceutical Expenditure 
Expensive innovative drugs, such as TNFalpha inhibitors, and an ageing population, who 
commonly suffer from one or more comorbidities, are serious challenges that may affect the 
sustainability of the Dutch healthcare system. To solve this problem a reform was implemented 
in 2012, aimed at the prospect of transferring many expensive drugs from retail to the hospital 
sector, increasing the bargaining power of hospitals and consequently leading to the purchase 
of pharmaceuticals at inferior prices. TNFalpha inhibitors were the first to be transferred in 
2012, followed by expensive cancer medicines and growth hormones in 2013, fertility 
hormones in 2014 and the remaining cancer medicines in 2015(53). Hospitals were 
compensated for the costs of these transferred medicines and had to agree with a fixed annual 
growth rate of expenditure of 1.5% in 2014, followed by 1% fixed annual growth until 2017. But 
expensive medicines have an expenditure growth rate far greater than the agreed growth rate, 
for example, the prices of new cancer medicines increased by 80% between 2011 and 2014, 
putting into question the feasibility of the agreed growth in hospital expenditure. Indeed, in 
2015, several hospitals complained to the Dutch Broadcast Foundation that they were no 
longer able to finance expensive medicines, even warning that their financial situation could 
jeopardise public access to these medicines. There were even reports of several clinicians 
confessing that their hospitals had rationed the use of expensive medicines(53).  
1.4. Portuguese healthcare system 
The Portuguese healthcare system is characterised by three coexisting, overlapping systems: 
The National Health Service (NHS), special public and private insurance schemes for certain 
professions (health subsystems), and private voluntary health insurance(VHI)(54). All 
residents in Portugal have access to healthcare provided by the NHS, financed mainly thru 
taxation. The existence of three different systems allows patients to benefit from triple 
coverage, that is, from the NHS, a health subsystem from their job and VHI. Pharmaceutical 
co-payment of retail dispensed prescribed drugs, under the NHS, is divided into four 
categories, category A has a reimbursement rate of 90% of the costs; category B, 69%; 
category C, 37%; and category D, 15%(54). TNFalpha inhibitors and many other drugs are 
excluded from this regiment and when prescribed for certain diseases, such as RA, the drug 
is 100% insured(54). These drugs, when prescribed by a rheumatologist in a specialised 
consultation, must be dispensed by the hospital pharmacy of the NHS with the costs being 






1.4.1. Pharmaceutical Expenditure 
Portugal’s Health expenditure has steadily reduced since the financial assistance of 2011 by 
“Troika”, which encompasses the European Commission (EC), the International Monetary 
Fund (IMF) and the European Central Bank (ECB). This reduction was conducted due to an 
excessive health expenditure as a percentage of GDP when compared to the EU’s average of 
9.5% in 2011(56). This reduction was particularly hard to accomplish because of two main 
reasons, first, treatment options tend to be more complex and costly to a population, that due 
to ageing, requires more medical treatments. Secondly, due to the financial crises, Portugal’s 
GDP decreased by around 5% between 2008 and 2013, making it necessary to compensate 
said decrease with an even bigger budget cut for health. Nevertheless, a great reduction in 
total health expenditure as a percentage of GDP was accomplished, and in 2013 it reached 
9,6%, almost identical to the EU average of 9,5%. But some signs of fragility on an already 
stressed system are starting to appear. The hospital sector which is taking the full brunt of the 
increasingly priced medication, such as immunomodulators and cancer drugs, is a clear 
example of this(57). Hospital debt rose by 27 million euros per month in 2016, and although 
this debt is not all pharmaceutical-related, it is estimated that the sum of all hospital debt to the 
pharmaceutical industry in 2016 is around 1.100 million euros(58,59).  
1.4.2. Regional differences in health providers 
Portugal is a country with big regional differences in educational, income, healthcare, and 
many others. These factors tend to privilege citizens that live near the coastal area, particularly 
in the central and northern regions. This inequality also has a big impact in patients with RA, 
since this disease is more prevalent in older individuals that tend to live in areas with fewer 
care providers. Figure 4 shows a clear geographical asymmetry on the estimated prevalence 
of undiagnosed patients, with some interior regions of Portugal being highlighted as having up 
to 70% of the total number of rheumatic patients, undiagnosed.  
In 2006 the European proportion of registered rheumatologists per inhabitant was around 
1:60.000, with Portugal and The Netherlands on the lower end of the spectrum with 1:100.000 
and 1:80.000, respectively, and France and Estonia on the upper end with 1:25.000 and 
1:35.000, respectively(60). In Portugal, the total number of rheumatologists has been 
increasing, with the intent of reaching the mark of 1:50.000(61). From 2008 to 2013 the 
proportion varied from approximately 1:95.000 to 1:72.000, respectively. However, it still looks 
that some regions, mainly Trás-os-Montes, Beira Interior or Algarve, are lagging behind the 
rest of the country due to an inferior amount of healthcare centres and an average of only 1 to 




Figure 4 - Estimative of the percentage of undiagnosed patients with rheumatic diseases. (61)  
2. Objectives 
2.1. General Objective 
Determine the variation in TNFalpha inhibitors utilization by RA patients in Portugal and in The 
Netherlands between 2008 and 2013. 
 
2.2. Specific Objectives 
1. Describe the main differences between treatment guidelines of RA in both countries; 
2. Assess the evolution of TNFalpha inhibitors utilization and patient’s access to biologic 
drugs between 2008 and 2013; 
3. Identify the possible reasons for usage and access variation of TNFalpha inhibitors in 
Portugal and in the Netherlands. 
 
3. Methodology 
This is a descriptive, retrospective and observational study that compares biological drug 
usage between Portugal and the Netherlands, within the class of TNFalpha inhibitors drugs. 
Countries were selected due to their similarity in population size and characteristics (e.g. age 
pyramid) and due to their differences regarding geographical location, GDP per capita, health 






3.1. Country and patient characteristics, biologic drug access 
determinants and treatment guidelines 
 
Population characteristics such as population size, demographics and RA prevalence, 
economic and expenditure factors such as GDP per capita, total health expenditure and 
medical goods expenditure and treatment guidelines were retrieved from a variety of sources 
(6,48,49,62–66). Rheumatologists per 100.000 inhabitants were determined according to the 
information provided by the NVR and by the Portuguese Order of Doctors(67).  
Characteristics of patients under therapy with biologic therapy in 2016 were determined 
according to the “Registo Nacional de Doentes Reumáticos” (Reuma.pt) 2016 report and 
University Medical Center Utrecht, for Portugal and the Netherlands, respectively. Reuma.pt 
is the Portuguese national registry for rheumatologic patients, with 16378 patients registered 
in 2016, of which 40.73% (6630 patients) were diagnosed with RA (68). The University Medical 
Center Utrecht is the main hospital of the city of Utrecht, located in the Province of Utrecht in 
the Netherlands, that at the time of this analysis had 1274 patients undergoing biologic therapy 
with the following TNFalpha inhibitors: L04AB01 - etanercept, L04AB02 - infliximab, L04AB04 
- adalimumab, L04AB05 – certolizumab pegol, L04AB06 - golimumab.  
To guaranty maximum comparability of RA prevalence in both countries, Kobelt et al(19) report 
was utilised.  
 
3.2. Utilisation data 
Table 3 provides an overview of the data sources for the utilisation data of TNFalpha inhibitors 
utilisation data in Portugal and the Netherlands. 
Usage data for Portugal represent the total consumption in all public hospitals in the country 
and it was presented according to the “Código Hospital Nacional do Medicamento” (CHNM), 
which identifies all medication with a specific and unique code, that doesn’t differentiate 
between the original drug and its generic/biosimilar counterpart.  
For the Netherlands, two sources of utilisation data were used, namely, the GIPdatabank, 
which contains information about outpatient care provided and paid in accordance with the 
Health Insurance Act(69) and the report “Evaluatie overheveling geneesmiddelen” by Erf et 
al.(70) which contains information on the national utilisation of these biologics shared by the 
Zorginstituut Nederland (ZIN).  
No accurate data on L04AB02 – infliximab utilisation was present in either Dutch databases 
and thus it was excluded from the analysis. Drug utilisation was measured using Anatomical 
Therapeutic Chemical Code (ATC)/DDD methodology since it functions as a common unit of 
consumption independent of drug price and dosage form(71,72). For the selected drugs, the 
24 
 
DDDs are as following: infliximab – 3.75mg; etanercept – 7mg; adalimumab – 2.9mg and 
golimumab – 1.66mg. DDDs were calculated according to the usual dose indicated for RA on 
each products’ Summary of Product Characteristics (SPC)(73–76). Utilisation is presented in 
DDDs/1000 inhabitants/day and it was calculated according to the number of inhabitants of 
each country on the 1st of January of each year.  
 
 Portugal Netherlands 
Data Source 
INFARMED – Autoridade 
Nacional do Medicamento e 
Produtos de Saude, I.P. 
GIPdatabank (70) 
 
Erf. et al(69) 
 
Period of drug 
utilisation data 
2008 to 2013 
2008 and 2009 - Gipdatabank 
 
2010 to 2013 – Erf et al(69) 
 
Drugs under analysis 
ATC 













Ustekinumab (L04AC05)  
 
Drug utilization  
ATC/DDD 
Etanercept – 7mg 
 Adalimumab – 2.9mg 
Golimumab – 1.66mg 









3.3. Patient access to biologics 
Patient access to biologics (PAB) is a variable calculated according to the following ratio(4):  
 
𝑃𝐴𝐵 =
𝑅ℎ𝑒𝑢𝑚𝑎𝑡𝑖𝑐 𝑝𝑎𝑡𝑖𝑒𝑛𝑡𝑠 𝑡𝑟𝑒𝑎𝑡𝑒𝑑 𝑤𝑖𝑡ℎ 𝑏𝑖𝑜𝑙𝑜𝑔𝑖𝑐𝑠
𝑇𝑜𝑡𝑎𝑙 𝑝𝑟𝑒𝑣𝑎𝑙𝑒𝑛𝑐𝑒 𝑜𝑓 𝑅𝐴
 (1)  
PAB is a measure that allows to quantify and compare biologic drug consumption while 
accounting for the total prevalence of a given disease in a given country.  
The number of patients treated was obtained via INFARMED – Autoridade Nacional do 
Medicamento e Produtos de Saude, I.P and GIPdatabank, for Portugal and the Netherlands, 
respectively. To account for the different possible therapeutically indications of biologic drugs, 
the following shares were estimated for etanercept, adalimumab and infliximab, 75%, 53% and 
39%, respectively, as done in previous works(4). All other drugs were accounted as having 


















4.  Results 
4.1. Countries characteristics 
Table 4 shows a summary of four main group of factors under analysis between 2008 and 
2013. Both countries possess a considerable percentage of citizens aged 65 or more, with 
Portugal leading with 19.6% in 2013, above the EU average of 18.3%. GDP per capita has 
decreased in both countries since 2008, but there remains a big gap in GDP per capita 
between both countries, with the Netherlands GDP reaching 51.425$, more than double 
Portugal’s 21.619$, in 2013.  
Health expenditure as a percentage of GDP in both countries was above the EU average of 
9.0% and 9.5%, for 2008 and 2013, respectively. In fact, the Netherlands, total health 
expenditure increased from 9.6% to 11.0%, during this period, while Portugal’s percentage 
decreased from 9.9% in 2008 to 9.6% in 2013. Since GDP varied greatly during this period 
figure 5 was developed to illustrate the variation in health expenditure in millions of dollars 
during the analysed period, in it is possible to observe that the health expenditure in Portugal 
remained relatively stable, while the Netherlands health expenditure increased slightly until 
2011, with a more significant increase in the two following years. 
Medical goods expenditure as a percentage of total health expenditure decreased in both 
countries, with a 5% decrease in Portugal during the research period and culminating in a 
percentage of 19.7% in 2013, compared to the Netherlands 12.2%. Retail and Hospital 
distribution of TNFalpha inhibitors was conducted in the Netherlands until 2012, being followed 
by the transition to a hospital distribution channel only. Portugal, on the other hand, maintained 
a hospital distribution channel through the research period. 
No significant differences were observed in the treatment guidelines of both countries, but it 
should be noted that only on the Dutch guidelines appear to be some flexibility regarding the 
initiation of bDMARDs therapy with a DAS28 score inferior to 3.2.  
A greater prevalence of specialized health professionals was observed in the Netherlands, that 
in 2013 presented a ratio of 1.71 rheumatologists per 100.000 inhabitants, compared to 

















   
Population (millions)(64) 16.4 – 16.8 10.6 – 10.5 496.0 – 500.9 
Population aged 65 years 
and over (% of total 
population)(63) 
14.9 -  17.1 17.9 – 19.6 17.2 – 18.3 
Prevalence RA (%) 0.46 0.47 - 
Economy and 
expenditure 
   
GDP per capita in 
US$(63) 
56.929 – 51.425 24.816 - 21.619 
37.844 - 
35.240 
Total health expenditure 
(% of GDP)(63) 
9.6 – 11.0 9.9 – 9.6 9.0 – 9.5 
Total health expenditure 
(million $)(63) 
60.680 – 71.132 16.729 – 15.476 - 
Medical goods 
expenditure 
(% of total health 
expenditure)(62) 
15.1 – 12.2 25.0 – 19.7 - 
Pharmaceutical 
expenditure, (PPP$ per 
capita)(63) 
4427 - 5170 2584 - 2634 3033 - 3419 
Biologic drug access 
determinants 
   
Rheumatologist per 
100.000 habitants 
1.61 – 1.71 1.05 - 1.37 - 
Distribution channel 







   
Treatment initiation One csDMARD One csDMARD One csDMARD 
Criteria required to initiate 
TNFalpha inhibitors 
“DAS ≥ 3.2 or 2.6 ≤ 
DAS < 3.2 and 
worsening of 
HAQ≥0.22 (6/6M)9 
or worsening x-ray 
scores: Larsen≥6/ 
/SvdH ≥5 (12/12M)10” 
“DAS ≥ 3.2 or       
2.6 ≤ DAS < 3.2 











Figure 5- Total health expenditure in millions of dollars, in Portugal and the Netherlands, during the period 
between 2008 and 2013. (64). 
Figure 5 represents with more detail the evolution of total health expenditure in both countries. 
Portugal’s expenditure stabilized until 2011, followed by a significant decrease in 2012 and 
2013. Netherlands, on the other hand, displayed a continues growth in expenditure, having 
increased around 15% of its total value in just five years. 
Table 5 presents an analysis of the gender and age of patients enrolled in biologic therapy in 
the Netherlands and in Portugal. Dutch patients under biologic therapy appear to be, on 
average, younger than Portuguese patients, particularly when undergoing therapy with the two 
main subcutaneous TNFalpha inhibitors, etanercept and adalimumab. A higher percentage of 
female patients compared to male patients was detected in both countries, with Portugal 
presenting the biggest gender disparity of around 2:1. 
 































Table 5 - Rheumatic patients’ characteristics of Portugal and The Netherlands in 2016 
4.2. Utilisation Data 
An increase in TNFalpha inhibitors has been noted in both countries, as noted in Figure 6. In 
Portugal, drug utilization increased from 0.18 DDDs/1000 inhabitants/day, in 2008, to 0.46 
DDDs/1000 inhabitants/day, in 2013. The Netherlands also displayed an increase from 0.98 
DDDs/1000 inhabitants/day, in 2008, to 1.64 DDDs/1000 inhabitants/day, in 2013. This latter 
increase resulted in a widening gap in drug utilisation between both countries, with the 
Netherlands having a surplus of around 0.80 DDDs/1000 inhabitants/day, in 2008 and of 1.19 
DDDs/1000 inhabitants/day, in 2013, when compared to Portugal’s utilisation during this 
period. 
PAB, as observed in figure 7, also increased in both countries, with a more notable increase 
in the Netherlands, which improved its PAB by approximately 20% between 2008 and 2013. 
While in Portugal, during the same time period, it increased around 4%. By the end of 2013, 
only approximately 7% of all Portuguese citizens afflicted with RA had access to TNFalpha 
inhibitors.  
 
 Netherlands Portugal 
Gender    
Female / Male (%) 
57.5 / 42.5 
(N= 1274) 
 
66.06 / 33.94 
(N = 4284) 
Age    
Mean age of patients 
under biologic treatment 
43.92 ± 20.56 
(N = 1274) 
 
51.18 ± 16.82 
(N = 4284) 
Mean age of patients 
under Infliximab treatment 
-  
52.51 ± 15.61 
(N = 415) 
Mean age of patients 
under Etanercept treatment 
42.65 ± 22.93 
(N = 313) 
 
50.3 ± 17.27 
(N = 1457) 
Mean age of patients 
under Adalimumab treatment 
43.68 ± 20.11 
(N = 862) 
 
48.13 ± 16.62 
(N = 915) 
Mean age of patients 
under Certolizumab Pegol 
treatment 
54.53 ± 12.51 
(N = 17) 
 
48.76 ± 14.04 
(N = 40) 
Mean age of patients 
under Golimumab treatment 
49.92 ± 20.56 
(N = 82) 
 
50.45 ± 13.24 






Figure 6- Utilisation of TNFalpha inhibitors in DDDs/1000 inhabitants/day, between 2008 and 2013 in Portugal 
and the Netherlands. 
 














































































This analysis indicates that there is a significant difference of TNFalpha inhibitors utilisation 
between the selected countries. As demonstrated in previous works(5), this difference in 
utilization appears to be increasing at a steady rate, even when the difference between the 
main factors correlated with an increased drug usage, in both countries, remained relatively 
constant. Health expenditure and GDP per capita, still seem to be two major factors that 
contribute to the expansion of biologic therapy use, but as seen during the analysed period, 
the influence of such factors on drug utilisation must be reevaluated. In both countries, GDP 
per capita and medical goods expenditure decrease significantly, and, in Portugal, this 
decrease was also accompanied by a decrease in health expenditure as a percentage of GDP, 
but still, an expansion of TNFalpha utilisation and PAB did occur.  
Health expenditure in millions of dollars remained relatively constant in Portugal between 2008 
and 2013, despite the increasing utilisation of TNFalpha inhibitors during this period. In the 
Netherlands health expenditure in millions of dollars increased slightly until 2011, the period in 
which utilisation increased more drastically, and then after 2011, a bigger increase in health 
expenditure was accompanied by a stabilization in drug utilisation as illustrated in figure 6. In 
fact, these results suggest that an increase in clinical efficiency and drug pricing renegotiation 
might have been conducted in Portugal, otherwise, it would have been very difficult to maintain 
such access to biologics while still maintaining such a reducing in expenditure with medical 
goods. In the Netherlands, this might have been also the case, due to the reduction in medical 
goods expenditure, but possibly to a lesser extent.  
Distribution channel, another factor argued to influence the utilisation of biologic drugs(4), also 
displayed a limited impact in TNFalpha utilisation, as noted in the Netherlands during the period 
of 2012 to 2013, where utilisation kept rising even after the transfer of biologics to a hospital 
only distribution channel in 2012. Granted that in 2012 a slight decrease in biologic utilisation 
occurred, but it was mainly due to a decrease in patients’ dosages, from an average of 301 
DDD per user, in 2012, to an average of 287 DDD per user, in 2013(70). While this alteration 
in dosages seems to have caused no significant impacted on patient health outcomes(70), it 
appears to have temporarily slowed down the increased in TNFalpha inhibitors utilisation.  
Treatment guidelines in both countries present limited differences, particularly when regarding 
the criteria required to initiate bDMARDs. However, there is a possible variation regarding the 
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adherence of clinicians to these guidelines, as noted in previous works, where Portuguese 
clinicians seem to have a somewhat limited adherence to clinical guidelines(5).  
As noted in previous works, there are multiple determinants of bDMARDs utilisation in Western 
European countries, such as GDP per capita, distribution channel, prevalence and total health 
expenditure(4,5). The fact that most of these determinants had their value decrease or stabilise 
during the entire analysed period, while TNFalpha inhibitors consumption kept on rising, is 
somewhat contradictory to what has been previously established in previous works(4,5). Some 
other factors were surely involved, other than biosimilar drugs since these were only introduced 
in 2013 and had no time to cause a significant impact on drug utilisation.     
Another important factor may also be used to explain this phenomenon of TNFalpha inhibitors 
utilisation and access in both countries, the number of rheumatologists per 100,000 
inhabitants, which increased in both countries during the research period. The Netherlands 
displayed a greater ratio of rheumatologists per 100,000 inhabitants than Portugal, both in 
2008 and in 2013, and as now surpassed the 1.67 ratio preconized as the required for 
European countries(77). Portugal, despite the considerable distance from the standard of 1.66, 
has also shown some progress and is now closer to meet this international standard. An 
increase in the number of rheumatologists may have led to a growth in RA detection and 
treatment, indirectly contributing to the observed upsurge of TNFalpha utilisation. 
Unfortunately for Portugal, the ratio of rheumatologists per 100,000 inhabitants is not enough 
to measure the real difficulty that patients face when trying to contact with specialists. Due to 
its severe desertification of the interior regions, it is estimated that some regions have 58% to 
70% of all rheumatic patients(61). Further increases in the number of a rheumatologist in 
Portugal may serve to attenuate this problem, but such measures will continue to have limited 
success on the overall drug utilisation of the country unless the problem of desertification is 
properly tackled.   
Mean age of patients under biologics in both countries also shows some noteworthy 
differences, Portuguese patients under bDMARDs therapy are, on average, older than their 
Dutch counterparts. This is likely due to a later diagnosis of RA paitiens in portuguese, as a 
consequence of the elevated number of undiagnosed patients in certain regions of the contry 
and of a lesser willingness to transition from csDMARDs to bDMRDS. Either scenario results 
in poor patient prognosis and in higher patient morbidity, as stated by EULAR(31). There 
should be noted that contrary to all other users of biologic drugs, Dutch patients under 
certolizumab pegol treatment appear to be older than their Portuguese counterparts, but this 
might be due to the smaller sample size of 17 and 40 patients for the Netherlands and Portugal, 
respectively.   
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It’s reasonable to assume that TNFalpha inhibitors utilisation will continue to increase, perhaps 
at a faster rate than that observed between 2008 and 2013, without causing a major impact on 
health expenditure. The impact of biosimilar drugs will be crucial to accomplish this result and 
all evidence indicates that it will be the case, especially when taking into account the prediction 
that drug expenditure with RA in the Netherlands could be reduced by 0.722 million euros in 
the first year after the introduction of one of its biosimilar drugs, Remsima®(39).  
Some limitations of this study should be noted. Dutch patient characteristics as presented in 
this work may lack nationwide representability since they were inferred from the analysis of a 
sample composed of a single hospital. The patients included where not differentiated 
according to diagnosis and thus there is the possibility that other non-rheumatic diseases might 
have affected the mean age of patients obtain. Prevalence data dates from Kobelt et al.(19) 
may be somewhat underestimated when considering the demographic shift present in Western 
European during the current decade, there is also the question regarding the now outdated 
diagnostic tools utilised by Kobelt et al.(19) that predate the new ACR/EULAR classification 
criteria. The DDD methodology does not necessarily replicate the clinical dosages of each 
pharmaceutical formulation, but it is also important to note that the difference does not account 
for a big variation in results. The fact that utilisation data of the Netherlands was only available 
on a aggregated form, lead. There is also an overrepresentation of TNFalpha inhibitors 
utilisation and PAB for RA since it was assumed to be the sole therapeutically indication of 
these drugs, which is not the case. But, as stated in previous works, RA is the main indication 
of TNFalpha inhibitors(5). Utilisation data of TNFalpha inhibitors in the Netherlands is lacking 
and in many cases incomplete, particularly after the transition of all TNFalpha inhibitors to the 
Hospital sector. This transfer resulted in some difficulties when trying to assert the full extent 
of drug utilisation, particularly for infliximab, which lead to the exclusion of this drug from this 
analysis. This has resulted in an underestimation of the entire utilisation of TNFalpha inhibitors 
in the Netherlands and Portugal since infliximab is one of the three most utilized TNFalpha 
inhibitors, of which around 30% of the total usage is estimated to be in the treatment of RA(4). 
Despite this limitation, it is still possible to draw some important conclusions about the way 










In conclusion, this study displays the remarkable improvement in TNFalpha inhibitors 
utilisation, measured in DDD’s utilised, in Portugal and in the Netherlands, despite the difficult 
conditions imposed by the recent economic recession. However, the increasing gap in biologic 
utilisation in between both countries is a real reason for concern. This gap is accentuated when 
we the mean age of patients under biologic therapy is considered 
It is time to reshape national priorities and policies to revert this increasing gap in bDMARD 
utilisation, or else Europeans will start to face growing discrepancies in health access that soon 
may not be tolerated. Treatment guidelines present small differences in the criteria to initiate 
biologic treatment, but divergence by practitioners is still questionable, particularly in Portugal. 
This variation in utilisation displayed by both countries, between 2008 and 2013, is 
multifactorial and it should be addressed as such. GDP per capita, health expenditure, 
distribution channel and treatment guidelines, by themselves, are not enough to explain the 
dynamic evolution of bDMARDs utilisation, particularly in times of economic recession and 
austerity measures. Other factors such as the increase in the ratio of rheumatologists per 
100,000 inhabitants, amplified clinical efficiency, a reduction of user dosages and a reduction 
of drug prices are likely to have played a significant role during this period and may serve as 
an explanation for the increasing utilisation of TNFalpha inhibitors noted during this period.  
It must never come a time of one’s prospect of having the best available treatment for their 
condition derives primarily from their nationality and not from their disease status. Biosimilar 
drugs might help bridge this gap, but it is still unclear if will be sufficient to accomplish such 
deed. 
Netherlands biologic utilisation data quality was subpar when compared to Portugal’s data. 
The lack of reliable publicly accessed information in the former, particularly after 2012, limited 
this analysis and made it more difficult to fully understand the level of access to biologics in 
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Annex 1: Estimated total number of patients with RA in Europe plus Turkey(19). 
 
 





Annex 3: Maximum achievable “discount rate”, symbolized by the biosimilar price as a % of initial 
originator price(78). 
 
Annex 4: 2013 Update of the EULAR recommendations for the treatment of RA(37). 
